Inventiva (NASDAQ:IVA) Price Target Cut to $36.00 by Analysts at HC Wainwright

Inventiva (NASDAQ:IVAGet Rating) had its price objective lowered by investment analysts at HC Wainwright from $42.00 to $36.00 in a research report issued to clients and investors on Friday, The Fly reports.

Inventiva Price Performance

IVA opened at $3.90 on Friday. The firm’s fifty day moving average is $4.54 and its two-hundred day moving average is $5.97. The company has a current ratio of 5.06, a quick ratio of 5.04 and a debt-to-equity ratio of 0.10. Inventiva has a twelve month low of $3.75 and a twelve month high of $15.78.

Institutional Investors Weigh In On Inventiva

An institutional investor recently raised its position in Inventiva stock. Yiheng Capital Management L.P. increased its stake in shares of Inventiva S.A. (NASDAQ:IVAGet Rating) by 59.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,640,253 shares of the company’s stock after acquiring an additional 982,679 shares during the period. Inventiva comprises about 0.9% of Yiheng Capital Management L.P.’s portfolio, making the stock its 21st largest position. Yiheng Capital Management L.P. owned about 6.46% of Inventiva worth $14,970,000 as of its most recent filing with the Securities & Exchange Commission. 22.29% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

(Get Rating)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

Recommended Stories

The Fly logo

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.